Xiao Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiao Hu has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Shangqin Guo
Department of Cell Biology, Yale University
4 shared publications Amaleah A. Hartman
Department of Cell Biology, Yale University, New Haven, Connecticut, USA
2 shared publications- Anna E. Eastman
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, USA
2 shared publications Dimin Li
Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China
2 shared publicationsDuanqing Pei
CAS Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China
2 shared publicationsJian Zhang
Department of Medical Genetics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
Targeting folate-dependent purine synthesis sensitizes melanoma cells to immune attack through suppressing glycolysis
Cytotoxic T lymphocytes (CTLs) play a central role in antitumor immunity; however, metabolic reprogramming within the tumor microenvironment often compromises their effector function, making metabolic targeting crucial for the improvement of T cell function. Folate-dependent purine synthesis, a core pathway sustaining the nucleotide pool, is highly activated in tumors, yet its role in regulating tumor immune sensitivity remains unclear. Here, by establishing a co-culture system of melanoma cells and human T Cell Receptor (TCR)-engineered T cells, we systematically evaluated the effects of folate-dependent purine synthesis inhibitors on tumor cell response to CD8+ T cell cytotoxicity. We found that inhibition of key enzymes such as methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and glycinamide ribonucleotide transformylase (GART) markedly enhanced tumor cell sensitivity to T cell killing, an effect also observed with exogenous nucleoside supplementation. Mechanistically, inhibition of folate-dependent purine synthesis suppresses glycolysis by downregulating critical glycolytic enzymes, thereby reducing lactate production. Reduction in lactate further weakens lactylation and stability of the immune checkpoint protein PD-L1. In parallel, impaired purine synthesis disrupts uridine metabolism, blocks ribose salvage, and distally influences glycolysis. Collectively, our study identified the folate-dependent purine synthesis – glycolysis axis as key regulator of tumor immune response and highlights metabolic targeting as a promising strategy to improve cancer immunotherapy.
Open AccessTargeting folate-dependent purine synthesis sensitizes melanoma cells to immune attack through suppressing glycolysis
Cytotoxic T lymphocytes (CTLs) play a central role in antitumor immunity; however, metabolic reprogramming within the tumor microenvironment often compromises their effector function, making metabolic targeting crucial for the improvement of T cell function. Folate-dependent purine synthesis, a core pathway sustaining the nucleotide pool, is highly activated in tumors, yet its role in regulating tumor immune sensitivity remains unclear. Here, by establishing a co-culture system of melanoma cells and human T Cell Receptor (TCR)-engineered T cells, we systematically evaluated the effects of folate-dependent purine synthesis inhibitors on tumor cell response to CD8+ T cell cytotoxicity. We found that inhibition of key enzymes such as methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) and glycinamide ribonucleotide transformylase (GART) markedly enhanced tumor cell sensitivity to T cell killing, an effect also observed with exogenous nucleoside supplementation. Mechanistically, inhibition of folate-dependent purine synthesis suppresses glycolysis by downregulating critical glycolytic enzymes, thereby reducing lactate production. Reduction in lactate further weakens lactylation and stability of the immune checkpoint protein PD-L1. In parallel, impaired purine synthesis disrupts uridine metabolism, blocks ribose salvage, and distally influences glycolysis. Collectively, our study identified the folate-dependent purine synthesis – glycolysis axis as key regulator of tumor immune response and highlights metabolic targeting as a promising strategy to improve cancer immunotherapy.
- Open Access
- 26 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Serum starvation-induced cholesterol reduction increases melanoma cell susceptibility to cytotoxic T lymphocyte killing
While calorie restriction has been suggested to reduce tumor incidence and slow tumor progression through promoting anti-tumor immune response, evidence disclosing how absence of specific nutrient component and alterations of its related metabolic pathways contribute to the process of anti-tumor immune response is still vague. Using human HLA-A*02:01 restricted New York esophageal squamous cell carcinoma-1 (NY-ESO-1) T cell receptor-engineered T (TCR-T) cells as a tool to investigate the impact from nutrient factors on tumor cells for targeted cytotoxicity, we serum-starved both human and murine melanoma cells and monitored their responses to TCR-T cell killing. Serum starvation sensitizes melanoma cells predominantly by reducing cholesterol availability without causing unwanted off-target effect, as supplementation of cholesterol compromises the sensitization toward TCR-T cell killing. In response to serum starvation, tumor cells upregulate cholesterol biogenesis pathways as a compensatory mechanism. Our study reveals the critical role of cholesterol reduction in mediating serum starvation-induced enhancement of anti-tumor immune response, highlighting the importance of plasma membrane composition in determining tumor cell response to TCR-T cell killing.
- 26 May 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessSerum starvation-induced cholesterol reduction increases melanoma cell susceptibility to cytotoxic T lymphocyte killing
While calorie restriction has been suggested to reduce tumor incidence and slow tumor progression through promoting anti-tumor immune response, evidence disclosing how absence of specific nutrient component and alterations of its related metabolic pathways contribute to the process of anti-tumor immune response is still vague. Using human HLA-A*02:01 restricted New York esophageal squamous cell carcinoma-1 (NY-ESO-1) T cell receptor-engineered T (TCR-T) cells as a tool to investigate the impact from nutrient factors on tumor cells for targeted cytotoxicity, we serum-starved both human and murine melanoma cells and monitored their responses to TCR-T cell killing. Serum starvation sensitizes melanoma cells predominantly by reducing cholesterol availability without causing unwanted off-target effect, as supplementation of cholesterol compromises the sensitization toward TCR-T cell killing. In response to serum starvation, tumor cells upregulate cholesterol biogenesis pathways as a compensatory mechanism. Our study reveals the critical role of cholesterol reduction in mediating serum starvation-induced enhancement of anti-tumor immune response, highlighting the importance of plasma membrane composition in determining tumor cell response to TCR-T cell killing.
- Top Cited PapersOpen Access
- 3 December 2024
- Published by Wiley in Cell Proliferation
- Vol. 58 (3) , e13779
Ferroptosis in Osteoarthritis: Towards Novel Therapeutic Strategy
Osteoarthritis (OA) is a chronic, degenerative joint disease primarily characterised by damage to the articular cartilage, synovitis and persistent pain, and has become one of the most common diseases worldwide. In OA cartilage, various forms of cell death have been identified, including apoptosis, necroptosis and autophagic cell death. Ever‐growing observations indicate that ferroptosis, a newly‐discovered iron‐dependent form of regulated cell death, is detrimental to OA occurrence and progression. In this review, we first analyse the pathogenetic mechanisms of OA by which iron overload, inflammatory response and mechanical stress contribute to ferroptosis. We then discuss how ferroptosis exacerbates OA progression, focusing on its impact on chondrocyte viability, synoviocyte populations and extracellular matrix integrity. Finally, we highlight several potential therapeutic strategies targeting ferroptosis that could be explored for the treatment of OA.
- 3 December 2024
- Published by Wiley in Cell Proliferation
- Vol. 58 (3) , e13779
Top Cited PapersOpen AccessFerroptosis in Osteoarthritis: Towards Novel Therapeutic Strategy
Osteoarthritis (OA) is a chronic, degenerative joint disease primarily characterised by damage to the articular cartilage, synovitis and persistent pain, and has become one of the most common diseases worldwide. In OA cartilage, various forms of cell death have been identified, including apoptosis, necroptosis and autophagic cell death. Ever‐growing observations indicate that ferroptosis, a newly‐discovered iron‐dependent form of regulated cell death, is detrimental to OA occurrence and progression. In this review, we first analyse the pathogenetic mechanisms of OA by which iron overload, inflammatory response and mechanical stress contribute to ferroptosis. We then discuss how ferroptosis exacerbates OA progression, focusing on its impact on chondrocyte viability, synoviocyte populations and extracellular matrix integrity. Finally, we highlight several potential therapeutic strategies targeting ferroptosis that could be explored for the treatment of OA.
- Open Access
- 30 June 2023
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 41 (10) , 907-915
Serum Response Factor Reduces Gene Expression Noise and Confers Cell State Stability
The role of serum response factor (Srf), a central mediator of actin dynamics and mechanical signaling, in cell identity regulation is debated to be either a stabilizer or a destabilizer. We investigated the role of Srf in cell fate stability using mouse pluripotent stem cells. Despite the fact that serum-containing cultures yield heterogeneous gene expression, deletion of Srf in mouse pluripotent stem cells leads to further exacerbated cell state heterogeneity. The exaggerated heterogeneity is detectible not only as increased lineage priming but also as the developmentally earlier 2C-like cell state. Thus, pluripotent cells explore more variety of cellular states in both directions of development surrounding naïve pluripotency, a behavior that is constrained by Srf. These results support that Srf functions as a cell state stabilizer, providing rationale for its functional modulation in cell fate intervention and engineering.
- 30 June 2023
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 41 (10) , 907-915
Open AccessSerum Response Factor Reduces Gene Expression Noise and Confers Cell State Stability
The role of serum response factor (Srf), a central mediator of actin dynamics and mechanical signaling, in cell identity regulation is debated to be either a stabilizer or a destabilizer. We investigated the role of Srf in cell fate stability using mouse pluripotent stem cells. Despite the fact that serum-containing cultures yield heterogeneous gene expression, deletion of Srf in mouse pluripotent stem cells leads to further exacerbated cell state heterogeneity. The exaggerated heterogeneity is detectible not only as increased lineage priming but also as the developmentally earlier 2C-like cell state. Thus, pluripotent cells explore more variety of cellular states in both directions of development surrounding naïve pluripotency, a behavior that is constrained by Srf. These results support that Srf functions as a cell state stabilizer, providing rationale for its functional modulation in cell fate intervention and engineering.
- 16 May 2022
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 86 (Pt 2) , 420-435
Cancer evolution: Special focus on the immune aspect of cancer
- 16 May 2022
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 86 (Pt 2) , 420-435
Cancer evolution: Special focus on the immune aspect of cancer
- Open Access
- 19 October 2020
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 39 (1) , 43-54
Reprogramming progressive cells display low CAG promoter activity
There is wide variability in the propensity of somatic cells to reprogram into pluripotency in response to the Yamanaka factors. How to segregate these variabilities to enrich for cells of specific traits that reprogram efficiently remains challenging. Here we report that the variability in reprogramming propensity is associated with the activity of the MKL1/SRF transcription factor and concurs with small cell size as well as rapid cell cycle. Reprogramming progressive cells can be prospectively identified by their low activity of a widely used synthetic promoter, CAG. CAGlow cells arise and expand during cell cycle acceleration in the early reprogramming culture of both mouse and human fibroblasts. Our work illustrates a molecular scenario underlying the distinct reprogramming propensities and demonstrates a convenient practical approach for their enrichment.
- 19 October 2020
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 39 (1) , 43-54
Open AccessReprogramming progressive cells display low CAG promoter activity
There is wide variability in the propensity of somatic cells to reprogram into pluripotency in response to the Yamanaka factors. How to segregate these variabilities to enrich for cells of specific traits that reprogram efficiently remains challenging. Here we report that the variability in reprogramming propensity is associated with the activity of the MKL1/SRF transcription factor and concurs with small cell size as well as rapid cell cycle. Reprogramming progressive cells can be prospectively identified by their low activity of a widely used synthetic promoter, CAG. CAGlow cells arise and expand during cell cycle acceleration in the early reprogramming culture of both mouse and human fibroblasts. Our work illustrates a molecular scenario underlying the distinct reprogramming propensities and demonstrates a convenient practical approach for their enrichment.
- Open Access
Reprogramming progressive cells display low CAG promoter activity
There is wide variability in the propensity of somatic cells to reprogram into pluripotency in response to the Yamanaka factors. How to segregate these variability to enrich for cells of specific traits that reprogram efficiently remains challenging. Here we report that the variability in reprogramming propensity is associated with the activity of the MKL1/SRF transcription factor and concurs with small cell size as well as rapid cell cycle. Reprogramming progressive cells can be prospectively identified by their low activity of a widely used synthetic promoter, CAG. CAG low cells arise and expand during cell cycle acceleration in the early reprogramming culture of both mouse and human fibroblasts. Our work illustrate a molecular scenario underlying the distinct reprogramming propensities and demonstrate a convenient practical approach for their enrichment.
Open AccessReprogramming progressive cells display low CAG promoter activity
There is wide variability in the propensity of somatic cells to reprogram into pluripotency in response to the Yamanaka factors. How to segregate these variability to enrich for cells of specific traits that reprogram efficiently remains challenging. Here we report that the variability in reprogramming propensity is associated with the activity of the MKL1/SRF transcription factor and concurs with small cell size as well as rapid cell cycle. Reprogramming progressive cells can be prospectively identified by their low activity of a widely used synthetic promoter, CAG. CAG low cells arise and expand during cell cycle acceleration in the early reprogramming culture of both mouse and human fibroblasts. Our work illustrate a molecular scenario underlying the distinct reprogramming propensities and demonstrate a convenient practical approach for their enrichment.
- Open Access
- 12 April 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
MKL1-actin pathway restricts chromatin accessibility and prevents mature pluripotency activation
Actin cytoskeleton is well-known for providing structural/mechanical support, but whether and how it regulates chromatin and cell fate reprogramming is far less clear. Here, we report that MKL1, the key transcriptional co-activator of many actin cytoskeletal genes, regulates genomic accessibility and cell fate reprogramming. The MKL1-actin pathway weakens during somatic cell reprogramming by pluripotency transcription factors. Cells that reprogram efficiently display low endogenous MKL1 and inhibition of actin polymerization promotes mature pluripotency activation. Sustained MKL1 expression at a level seen in typical fibroblasts yields excessive actin cytoskeleton, decreases nuclear volume and reduces global chromatin accessibility, stalling cells on their trajectory toward mature pluripotency. In addition, the MKL1-actin imposed block of pluripotency can be bypassed, at least partially, when the Sun2-containing linker of the nucleoskeleton and cytoskeleton (LINC) complex is inhibited. Thus, we unveil a previously unappreciated aspect of control on chromatin and cell fate reprogramming exerted by the MKL1-actin pathway.
- 12 April 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-13
Open AccessMKL1-actin pathway restricts chromatin accessibility and prevents mature pluripotency activation
Actin cytoskeleton is well-known for providing structural/mechanical support, but whether and how it regulates chromatin and cell fate reprogramming is far less clear. Here, we report that MKL1, the key transcriptional co-activator of many actin cytoskeletal genes, regulates genomic accessibility and cell fate reprogramming. The MKL1-actin pathway weakens during somatic cell reprogramming by pluripotency transcription factors. Cells that reprogram efficiently display low endogenous MKL1 and inhibition of actin polymerization promotes mature pluripotency activation. Sustained MKL1 expression at a level seen in typical fibroblasts yields excessive actin cytoskeleton, decreases nuclear volume and reduces global chromatin accessibility, stalling cells on their trajectory toward mature pluripotency. In addition, the MKL1-actin imposed block of pluripotency can be bypassed, at least partially, when the Sun2-containing linker of the nucleoskeleton and cytoskeleton (LINC) complex is inhibited. Thus, we unveil a previously unappreciated aspect of control on chromatin and cell fate reprogramming exerted by the MKL1-actin pathway.
- 27 June 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 66 (6) , 2002-2015
Pericentral hepatocytes produce insulin‐like growth factor‐2 to promote liver regeneration during selected injuries in mice
Liver regeneration (LR) happens after various types of injuries. Unlike the well‐studied LR caused by partial hepatectomy (PHx), there is accumulating evidence suggesting that LR during other injuries may result from unknown mechanisms. In this study, we found that insulin‐like growth factor 2 (IGF‐2) was drastically induced following the liver injuries caused by tyrosinemia or long‐term treatments of CCl4. However, this was not observed during the early phase of acute liver injuries after PHx or single treatment of CCl4. Remarkably, most IGF‐2‐expressing hepatocytes were located at the histological area around the central vein of the liver lobule after the liver injuries caused either in fumarylacetoacetate hydrolase–deficient mice or in CCl4 chronically treated mice. Hepatocyte proliferation in vivo was significantly promoted by induced IGF‐2 overexpression, which could be inhibited by adeno‐associated virus–delivered IGF‐2 short hairpin RNAs or linsitinib, an inhibitor of IGF‐2 signaling. Proliferating hepatocytes in vivo responded to IGF‐2 through both insulin receptor and IGF‐1 receptor. IGF‐2 also significantly promoted DNA synthesis of primary hepatocytes in vitro. More interestingly, the significantly induced IGF‐2 was also found to colocalize with glutamine synthetase in the region enriched with proliferating hepatocytes for the liver samples from patients with liver fibrosis. Conclusion: IGF‐2 is produced by pericentral hepatocytes to promote hepatocyte proliferation and repair tissue damage in the setting of chronic liver injury, which is distinct from the signaling that occurs post‐PHx. (Hepatology 2017;66:2002–2015)
- 27 June 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 66 (6) , 2002-2015
Pericentral hepatocytes produce insulin‐like growth factor‐2 to promote liver regeneration during selected injuries in mice
Liver regeneration (LR) happens after various types of injuries. Unlike the well‐studied LR caused by partial hepatectomy (PHx), there is accumulating evidence suggesting that LR during other injuries may result from unknown mechanisms. In this study, we found that insulin‐like growth factor 2 (IGF‐2) was drastically induced following the liver injuries caused by tyrosinemia or long‐term treatments of CCl4. However, this was not observed during the early phase of acute liver injuries after PHx or single treatment of CCl4. Remarkably, most IGF‐2‐expressing hepatocytes were located at the histological area around the central vein of the liver lobule after the liver injuries caused either in fumarylacetoacetate hydrolase–deficient mice or in CCl4 chronically treated mice. Hepatocyte proliferation in vivo was significantly promoted by induced IGF‐2 overexpression, which could be inhibited by adeno‐associated virus–delivered IGF‐2 short hairpin RNAs or linsitinib, an inhibitor of IGF‐2 signaling. Proliferating hepatocytes in vivo responded to IGF‐2 through both insulin receptor and IGF‐1 receptor. IGF‐2 also significantly promoted DNA synthesis of primary hepatocytes in vitro. More interestingly, the significantly induced IGF‐2 was also found to colocalize with glutamine synthetase in the region enriched with proliferating hepatocytes for the liver samples from patients with liver fibrosis. Conclusion: IGF‐2 is produced by pericentral hepatocytes to promote hepatocyte proliferation and repair tissue damage in the setting of chronic liver injury, which is distinct from the signaling that occurs post‐PHx. (Hepatology 2017;66:2002–2015)
- 1 April 2014
- Published by Elsevier in Cell Stem Cell
- Vol. 14 (4) , 512-522
Tet and TDG Mediate DNA Demethylation Essential for Mesenchymal-to-Epithelial Transition in Somatic Cell Reprogramming
- 1 April 2014
- Published by Elsevier in Cell Stem Cell
- Vol. 14 (4) , 512-522
Tet and TDG Mediate DNA Demethylation Essential for Mesenchymal-to-Epithelial Transition in Somatic Cell Reprogramming